Given recent OS data from the OlympiA trial, would you offer adjuvant olaparib to a BRCA+ patient with pT1bN0 TNBC?

Ref: Geyer et al, Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022 Dec;33(12):1250-1268. Does OS benefit compel you to try to expand your use of adjuvant olaparib?

Community PollStarted

Given latest OS data in the OlympiA trial, would you offer adjuvant olaparib to a BRCA+ patient with pT1bN0 TNBC?

62 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer

Mednet Member

Medical Oncology · Sarah Cannon Cancer Institute at Menorah Medical Center

Answered on

I would not, as those patients were not included in OlympiA.

Join for free or sign in to see the full answer